PMID- 21821532
OWN - NLM
STAT- MEDLINE
DCOM- 20120213
LR  - 20110808
IS  - 1940-4034 (Electronic)
IS  - 1074-2484 (Linking)
VI  - 16
IP  - 3-4
DP  - 2011 Sep-Dec
TI  - Infarct size reduction in patients with STEMI: why we can do it!
PG  - 298-303
LID - 10.1177/1074248411412379 [doi]
AB  - Major progress has been made over the last three decades for the treatment of 
      patients with ST elevation myocardial infarction (STEMI). The major objective of 
      this treatment is to reduce infarct size, which is the major prognostic factor in 
      this population. Most of the efforts have been focused on improving reperfusion 
      therapy in order to open as quickly as possible, and to prevent reocclusion, of 
      the culprit coronary artery. During the past years, preclinical research has 
      allowed researchers to well-characterize animal models of acute MI and precisely 
      describe the major determinants of infarct size, that is area at risk, collateral 
      flow, duration of ischemia, and timing of the protective intervention with 
      respect to reflow. Recent reports have clearly demonstrated that lethal 
      reperfusion injury exists, that it is of significant importance, and that it can 
      be prevented by protective interventions applied immediately before reflow. Time 
      has come to, on top of reperfusion therapy, better protect the muscle against 
      lethal reperfusion injury. Although many past infarct size reduction studies have 
      been negative, recent proof-of-concept studies have shown that infarct size 
      reduction is possible in patients with STEMI, at least in part because the major 
      determinants of infarct size have been taken into account. Accumulated knowledge 
      from animal models together with encouraging results obtained in phase II infarct 
      size reduction clinical trials should help us improve the design of future 
      studies aimed at reducing infarct size in patients with STEMI.
FAU - Mewton, Nathan
AU  - Mewton N
AD  - Inserm U 1060, CARMEN, Lyon, France.
FAU - Elbaz, Meier
AU  - Elbaz M
FAU - Piot, Christophe
AU  - Piot C
FAU - Ovize, Michel
AU  - Ovize M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Cardiovasc Pharmacol Ther
JT  - Journal of cardiovascular pharmacology and therapeutics
JID - 9602617
SB  - IM
MH  - Animals
MH  - Arrhythmias, Cardiac/*physiopathology
MH  - Disease Models, Animal
MH  - Electrocardiography
MH  - Humans
MH  - Myocardial Infarction/pathology/physiopathology/*prevention & control/*therapy
MH  - Myocardial Reperfusion/*methods
MH  - Myocardial Reperfusion Injury/drug therapy/physiopathology/*prevention & 
      control/therapy
EDAT- 2011/08/09 06:00
MHDA- 2012/02/14 06:00
CRDT- 2011/08/09 06:00
PHST- 2011/08/09 06:00 [entrez]
PHST- 2011/08/09 06:00 [pubmed]
PHST- 2012/02/14 06:00 [medline]
AID - 16/3-4/298 [pii]
AID - 10.1177/1074248411412379 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):298-303. doi: 
      10.1177/1074248411412379.